Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib
Yonsei Medical Journal
;
: 931-939, 2012.
Article
in English
| WPRIM
| ID: wpr-228779
ABSTRACT
PURPOSE:
The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. MATERIALS ANDMETHODS:
Pretreatment CEA and CYFRA 21-1 were measured in 123 advanced NSCLC patients receiving gefitinib or erlotinib. High CEA levels (h-CEA) were significantly associated with females, patients with adenocarcinoma, and non-smokers.RESULTS:
Low CYFRA 21-1 levels (l-CYFRA) were significantly associated with a good performance status (ECOG PS 0-1). The overall response rate (RR) was 27.6%, and higher RR was associated with adenocarcinoma, h-CEA, and epidermal growth factor receptor (EGFR) mutation. Patients with h-CEA had significantly longer progression-free survival (PFS) (p=0.021). Patients with l-CYFRA had significantly longer PFS and overall survival (p=0.006 and p<0.001, respectively). Of note, h-CEA and l-CYFRA had good prognosis in patients with unknown EGFR mutation status or patients with squamous cell carcinoma (p=0.021 and p=0.015, respectively). A good ECOG PS (HR=0.45, p=0.017), h-CEA (HR=0.41, p=0.007), l-CYFRA 21-1 (HR=0.52, p=0.025), and an EGFR mutation (HR=0.22, p<0.001) were independently predictive of a longer PFS.CONCLUSION:
h-CEA and l-CYFRA 21-1 may be prognostic and predictive serum markers for higher response and longer survival in patients with advanced NSCLC receiving gefitinib or erlotinib, especially in patients with unknown EGFR mutation status or patients with squamous cell carcinoma.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Carcinoma, Squamous Cell
/
Biomarkers
/
Adenocarcinoma
/
Carcinoembryonic Antigen
/
Carcinoma, Non-Small-Cell Lung
/
Disease-Free Survival
/
Keratin-19
/
ErbB Receptors
/
Erlotinib Hydrochloride
Type of study:
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Yonsei Medical Journal
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS